Login / Signup

Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.

Yu OzawaSunao NoharaKen NakamuraSeiya HattoriYasuto YagiToru NishiyamaAtsunori YorozuTetsuo MonmaShiro Saito
Published in: The Prostate (2024)
A low number of prostate core biopsies results in worse BCR-free survival after brachytherapy as monotherapy in patients with cT1c PCa.
Keyphrases